The tumor doesn't exist alone—it's surrounded by a biological fortress
Por más de dos décadas, el glioblastoma ha desafiado a la medicina con una ferocidad casi sin igual, arrebatando vidas en apenas 15 meses y resistiendo cada intento de avance terapéutico. Investigadores de la Universidad McMaster han desarrollado una inmunoterapia experimental con células CAR-T que, en estudios preclínicos, logró eliminar tumores al atacar no solo las células cancerosas, sino también el entorno biológico que las sostiene. Es un recordatorio de que el progreso científico no siempre llega en línea recta, sino a veces como un giro inesperado que abre puertas que parecían selladas para siempre.
- El glioblastoma sigue siendo uno de los cánceres más letales conocidos: el 20 años de estancamiento terapéutico ha dejado a los pacientes sin opciones reales más allá de cirugía, radiación y quimioterapia.
- La nueva terapia CAR-T dirigida al receptor uPAR no solo destruye las células tumorales, sino que desmantelar el andamiaje biológico que permite al tumor sobrevivir y regenerarse tras los tratamientos convencionales.
- El equipo de McMaster, en colaboración con el Consejo Nacional de Investigación de Canadá, ya prepara el salto a ensayos clínicos en humanos, el paso más crítico y incierto en el largo camino hacia una terapia aprobada.
- Centros como Memorial Sloan Kettering y la Universidad de Columbia exploran si esta misma estrategia podría aplicarse a otros cánceres agresivos como el de pulmón y páncreas, ampliando el horizonte de lo que podría ser posible.
Investigadores de la Universidad McMaster han desarrollado una inmunoterapia experimental que, en estudios de laboratorio, logró eliminar tumores de glioblastoma, el cáncer cerebral primario más agresivo en adultos. El hallazgo, publicado en Science Translational Medicine, representa un destello de esperanza en una enfermedad que mata a la mayoría de los pacientes en apenas 15 meses y que ha resistido avances significativos durante más de dos décadas.
Lo que distingue a esta terapia de células CAR-T es su doble objetivo: no se limita a atacar las células cancerosas, sino que también destruye el entorno biológico que rodea al tumor, esa infraestructura invisible que permite a las células malignas sobrevivir, ocultarse y reaparecer después de la cirugía, la radiación o la quimioterapia. La terapia apunta a una proteína llamada receptor de uroquinasa, o uPAR, presente en la superficie de las células del glioblastoma.
Sheila Singh, cirujana e investigadora principal del proyecto, no oculta la urgencia que impulsa este trabajo. El tratamiento estándar del glioblastoma prácticamente no ha cambiado desde principios de los años 2000, y la enfermedad sigue siendo invariablemente fatal. El equipo desarrolló la terapia junto con científicos del Consejo Nacional de Investigación de Canadá, quienes crearon los anticuerpos que forman el núcleo del tratamiento experimental.
Las implicaciones podrían ir más allá del glioblastoma: centros como Memorial Sloan Kettering y la Universidad de Columbia ya investigan si atacar el uPAR podría ser eficaz contra otros tumores agresivos, incluidos los de pulmón y páncreas. Por ahora, el equipo de McMaster se prepara para iniciar ensayos clínicos en humanos, consciente de que el camino del laboratorio a la clínica es largo e incierto, pero convencido de que, para una enfermedad tan devastadora, incluso una señal prometedora representa un cambio en lo que parecía posible.
Researchers at McMaster University have engineered an experimental immunotherapy that eliminated glioblastoma tumors in laboratory studies, offering a potential breakthrough against one of the most lethal cancers known to medicine. The work, published in Science Translational Medicine, targets glioblastoma—the most aggressive primary brain cancer in adults—a disease that has resisted meaningful progress for more than two decades and kills most patients within 15 months of diagnosis.
The treatment is a chimeric antigen receptor T cell therapy, or CAR-T cell, designed to hunt down a protein called uroquinase receptor, or uPAR, that appears on the surface of glioblastoma cells. What makes this approach distinctive is that it does not simply attack the cancer cells themselves. It also targets the biological scaffolding surrounding the tumor—the infrastructure that allows malignant cells to survive, hide, and regrow after conventional treatments like surgery, radiation, or chemotherapy have failed. By dismantling both the tumor and its supporting ecosystem, the therapy addresses a fundamental reason why glioblastoma has proven so difficult to cure.
Sheila Singh, the lead researcher and a surgeon at McMaster, underscores the desperation underlying this work. The standard treatment for glioblastoma has barely changed in over 20 years. Patients still face surgery, radiation, and chemotherapy—the same arsenal deployed since the early 2000s. Yet the disease remains invariably fatal. Singh and her team developed this therapy in partnership with scientists at Canada's National Research Council, who created the antibodies that form the core of the experimental treatment. The collaboration brought together expertise in immunology and cancer biology that neither institution could have mustered alone.
The implications extend beyond glioblastoma. Other major cancer research centers—Memorial Sloan Kettering Cancer Center and Columbia University among them—are now investigating whether targeting uPAR might work against other aggressive malignancies, including lung and pancreatic cancers. If those efforts succeed, the strategy could reshape how researchers approach a whole class of hard-to-treat tumors. For now, though, the focus remains on moving from the laboratory to human patients.
Singh describes the current candidate as very promising and says the team is already preparing to launch clinical trials in humans. The path from preclinical success to approved therapy is long and uncertain—many drugs that work in the lab fail in people—but for a disease as uniformly deadly as glioblastoma, even a promising early signal represents a shift in what seemed possible. The next phase will test whether what worked in cells and animal models can translate into actual survival and quality of life for patients who have run out of other options.
Notable Quotes
The disease remains invariably fatal, and new therapies are urgently needed— Sheila Singh, lead researcher, McMaster University
This is a very promising clinical candidate, and we are working to move these preclinical results into the first human studies— Sheila Singh
The Hearth Conversation Another angle on the story
Why has glioblastoma treatment stalled for so long? What makes it different from other cancers that have seen real progress?
Glioblastoma is protected by its location and its biology. It sits in the brain, which is hard to reach with drugs. But more fundamentally, the tumor doesn't exist alone—it's surrounded by a kind of biological fortress that keeps it alive and helps it hide from the immune system. Standard treatments can shrink the visible tumor, but they leave that fortress intact, so the cancer comes roaring back.
And this new therapy—the CAR-T cell—it's designed to demolish that fortress too?
Exactly. It's not just hunting cancer cells. It's targeting uPAR, a protein that appears both on the tumor itself and on the cells and structures that support it. So you're attacking the whole ecosystem, not just the tumor.
How confident are the researchers that this will actually work in people?
They're cautiously optimistic. In the lab, it eliminated tumors completely. But there's always a gap between what works in a dish and what works in a human body. That's why they're moving to clinical trials now. For a disease where almost everyone dies within 15 months, even a promising signal is worth pursuing.
Why are other cancer centers suddenly interested in uPAR?
Because if this protein is a vulnerability in glioblastoma, it might be a vulnerability in other aggressive cancers too—lung, pancreas. If the strategy works broadly, you're not just treating one disease. You're opening a new door for a whole category of hard-to-treat tumors.
What's the realistic timeline for patients to access this?
Clinical trials will take years. Even if everything goes well, you're looking at several years before this could become a standard treatment. But for glioblastoma patients, the alternative is the same treatment that's been failing for 20 years. So there's real urgency here.